Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00090194 · ClinicalTrials.gov registry record · Phase 2
Improving Transplant Options of Highly Sensitized Recipients Using IGIV-C, 10%
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Terminated
- Registry status
- Phase 2
- Development phase
- 56
- Enrollment target
NCT00090194 is a Phase 2 study that was terminated before completion, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 56 participants.
The verdict
NCT00090194, a Phase 2 study, was terminated before completion, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 56 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if IGIV-C, 10% will be effective in converting a donor-recipient crossmatch status from positive to negative. The crossmatch test is used to determine if the donor tissue and recipient tissue are compatible. The study will also evaluate if IGIV-C, 10% will allow successful kidney transplantation in a patient who otherwise would not be able to receive a transplant. Three dose levels of IGIV-C, 10% will be evaluated to determine what dose level is most effective.
Interventions
- BIOLOGICAL Immune Globulin Intravenous (Human), 10%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2003-06 |
| Est. Completion | 2004-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00090194
The ClinicalTrials.gov registry entry for NCT00090194 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Immune Globulin Intravenous (Human), 10% is the first listed.
NCT00090194 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00090194 about?
NCT00090194 is a clinical study titled "Improving Transplant Options of Highly Sensitized Recipients Using IGIV-C, 10%". The purpose of this study is to determine if IGIV-C, 10% will be effective in converting a donor-recipient crossmatch status from positive to negative. The crossmatch test is used to determine if the donor tissue and recipient tissue are compatible. The study will also evaluate if IGIV-C, 10% will a...
What is the current status of trial NCT00090194?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 56 participants. The study started on 2003-06. Estimated completion is 2004-03.
What interventions are being tested in trial NCT00090194?
The interventions under investigation include: Immune Globulin Intravenous (Human), 10% (BIOLOGICAL).
Who is sponsoring clinical trial NCT00090194?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.